Provided by Tiger Fintech (Singapore) Pte. Ltd.

COYA THERAPEUTICS INC

6.32
+0.03500.56%
Volume:11.40K
Turnover:71.93K
Market Cap:105.62M
PE:-6.47
High:6.48
Open:6.34
Low:6.26
Close:6.28
Loading ...

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Dow Jones
·
18 Mar

Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

TIPRANKS
·
03 Mar

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Benzinga
·
07 Feb

Coya Therapeutics up 8% on Positive Results From Mid-Stage Alzheimer’s Disease Trial

THOMSON REUTERS
·
06 Feb

Coya Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
06 Feb

BRIEF-Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients

Reuters
·
06 Feb

Coya: Low-Dose IL-2 in AD patients resulted in reduced proinflammatory markers

TIPRANKS
·
06 Feb

Coya Therapeutics Inc - Ld Il-2 Well-Tolerated With No Serious Adverse Events Reported

THOMSON REUTERS
·
06 Feb

Coya Therapeutics Inc - Reports Significant Improvement in Inflammatory Markers in Alzheimer's Patients

THOMSON REUTERS
·
06 Feb

Coya Therapeutics Inc - Monthly Ld Il-2 Shows Significant Reduction in Ccl2 and Il-15, Increase in Il-4

THOMSON REUTERS
·
06 Feb

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Business Wire
·
06 Feb

Coya Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Jan

Coya Therapeutics Announces Pipeline Expansion - Coya 303: Coya 301 in Combination With Glp-1 Receptor Agonist for the Treatment of Inflammatory Diseases

THOMSON REUTERS
·
21 Jan

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

Benzinga
·
21 Jan

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (Ld Il-2) + Ctla4-Ig Fusion Protein in Patients With Frontotemporal Dementia (Ftd)

THOMSON REUTERS
·
18 Dec 2024

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Business Wire
·
18 Dec 2024

Coya Therapeutics initiated with a Buy at D. Boral Capital

TIPRANKS
·
04 Dec 2024

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Business Wire
·
25 Nov 2024

Coya Therapeutics files to sell 1.38M shares of common stock for holders

TIPRANKS
·
21 Nov 2024

BRIEF-Coya Therapeutics Inc Files For Resale Of Up To 1.4 Million Shares By The Selling Stockholders - SEC Filing

Reuters
·
21 Nov 2024